34 results about "HomoloGene" patented technology

LSD1, a homolog of nuclear amine oxidases, functions as a histone demethylase and transcriptional co-repressor. LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription. Lysine demethylation occurs via an oxidation reaction that generates formaldehyde. Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4 methylation and concomitant de-repression of target genes, suggesting that LSD1 represses transcription via histone demethylation. The results thus identify a histone demethylase conserved from S. pombe to human and reveal dynamic regulation of histone methylation by both histone methylases and demethylases.

This present invention is directed to polypeptide and polynucleotide molecules that encode a new connective tissue growth factor homolog polypeptide. The human polypeptides have been designated zCTGF4 and the mouse orthologs have been designated zCTGF2. The invention also includes antibodies, expression vectors, host cells expressing zCTGF4 and variants. Also included are methods for producing the polypeptides and using the polynucleotides and polypeptides.

The present invention relates to a method for identifying a substance capable of disrupting an interaction between (i) a herpes simplex virus (HSV) ICP34.5 polypeptide or a homologue thereof, or a derivative thereof, and (ii) proliferating cell nuclear antigen (PCNA) or a homologue thereof, or a derivative thereof. The method comprises: (a) providing an HSV ICP34.5 polypeptide or a homologue thereof, or a derivative thereof, as a first component; (b) providing PCNA, or a homologue thereof, or a derivative thereof, as a second component; (c) contacting the two components with a substance to be tested under conditions that would permit the two components to interact in the absence of the substance; and (d) determining whether the substance disrupts the interaction between the first and second components.

The invention belongs to the technical field of fermentation and discloses a method for directional accumulation of specific homolog components of antimicrobial lipopeptides of bacilli. Bacillus natto NT-6 strains serve as original strains, Landy serves as a culture medium, culture is performed at 28-32 DEG C for 36-48 h under the condition of 160 r/min, and the specific components comprise Iturins containing homologs with cytoplasmic-nuclear ratios being 1044.30, 1057.20 and 1071.20 and Surfactins containing homologs with cytoplasmic-nuclear ratios being 995.20, 1008.20, 1022.30 and 1058.20. With the adoption of the method, directional accumulation can be performed on the specific homolog components of the antimicrobial lipopeptides of the bacilli by controlling the fermentation culture medium and fermentation conditions, lipopeptide products comprising different specific homolog components and having specific ratios of the specific homolog components can be produced, so that effects of the lipopeptide products are improved, and the use range of the lipopeptide products is expanded.

Isolated polynucleotides and polypeptides and recombinant DNA constructs particularly useful for altering root structure of plants, compositions (such as plants or seeds) comprising these recombinant DNA constructs, and methods utilizing these recombinant DNA constructs. The recombinant DNA construct comprises a polynucleotide operably linked to a promoter functional in a plant, wherein said polynucleotide encodes a polypeptide useful for altering plant root architecture.

Plynucleotides encoding a novel Drosophila gene product designated mus101 and homologues thereof as well as mus101 polypeptides are provided. Polynucleotide probes derived from the nucleotide sequence of mus101 and antibodies that bind to mus101 protein are also provided as well as assays for identifying substances that regulate mus101 function.

The invention discloses a method for quantitatively detecting the target protein yield of a cell-free protein synthesis system and screening zymoprotein with high catalytic activity. According to the method for quantitatively detecting the yield of the target protein in the CFPS system, the expression quantity of the target protein in the CFPS system can be rapidly analyzed by segmenting the intensity value of fluorescence emitted by spontaneous binding of fluorescent protein, and rapid detection of the expression quantity of the target protein in the CFPS system is facilitated; meanwhile, based on the method, the enzyme homologues with high catalytic activity can be quickly screened by calculating the ratio of the quantity of products obtained by catalysis of each enzyme protein to the fluorescence intensity value after spontaneous binding of segmented fluorescent protein, and a conventional large intestine transformation-expression-purification process is not needed, so that the time and the material cost are greatly saved, the screening speed is increased, and moreover, the screening leakage risk of the high-catalytic-activity protein caused by too low protein expression quantity is avoided, and rapid and accurate screening of the high-catalytic-activity zymoprotein is facilitated.

We recently found that Satb1 is expressed highly by mature neurons in specific regions of the postnatal brain. Satb2, a homolog of Satb1, is expressed at low levels in the postnatal brain. Neurons respond to external stimuli and rapidly and dynamically change their expression. Satb1 has been found to directly regulate a set of genes in the postnatal brain, presumably playing a crucial role as a ‘genome organizer’ for brain function and behaviors. Satb2 may also have a similar function, even though it is expressed at low levels in the postnatal brain. The present invention describes compositions, reagents and tools using wild type and variant SATB1 and SATB2 genes and proteins for use in diagnosis, prognosis and therapeutics in neurological dysfunction and psychiatric disorders.

The present invention provides OX2 receptor homologs. The present invention also provides nucleic acids encoding mammalian, e.g., primate, receptors of OX2, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Method of using the compositions for both diagnostic and therapeutic utilities are described.

The invention discloses a method for regulating and controlling the components of a polymyxin B homolog. The method comprises the following steps: (1) constructing pMAD-DeltaA and pMAD-DeltaC; (2) transforming pMAD-DeltaA into CJX518 strains, conducting screening to obtain successfully-transformed strains, performing culturing and subculturing to obtain plasmid-lost strains, verifying the plasmid-lost strains as structural domain-replaced strains 518-A through PCR sequencing, transforming pMAD-DeltaC into the CJX518 strains, screening the pMAD-DeltaC transformed strains 518-A, carrying out culturing and subculturing to obtain plasmid-lost strains, and verifying the plasmid-lost strain as structural domain-replaced strains 518-AC through PCR sequencing; (3) carrying out seed culture to obtain secondary seeds; and (4) producing polymyxin B by inoculating the secondary seeds into a fermentation medium, and carrying out fermenting for 72 hours. According to the method disclosed by the invention, the components of the polymyxin B homolog are regulated and controlled, a ratio of B1 to B2 is increased, and a ratio of B3 to B1-1 is reduced.

The present invention relates to a novel mammalian-derived enzyme, histidine protein phosphatase, and homologue variants thereof. The invention also relates to DNA sequences encoding said proteins, methods for preparing said proteins and antibodies against them. This novel phosphatase is useful in the diagnosis of pathological states of cell regulation and cell growth, and as a drug for the treatment of pathological diseases associated with said enzyme disorders.

Compositions and methods for detection of protein interaction with a target biomolecule are provided. Compositions can include biomolecule sensors having at least a genetically modified ubiquitin peptide; an ADP-Ribosyltransferase (ART) peptide domain of a SidE-ligase protein or a homolog thereof; and a phosphodiesterase (PDE) domain of a SidE-ligase protein or a homolog thereof.

Provided are an oncolytic virus for treating brain tumors using a recombinant Newcastle disease virus into which a Newcastle disease virus (NDV) vector-based PTEN (phosphatase and tensin homolog) gene is inserted and a composition for treating brain tumors using the same which can be used for a therapeutic viral agent that can induce reduction of clinical symptoms or partial or complete remission through brain tumor cell death or brain tumor tissue reduction by expressing normal PTEN protein after being infected with brain tumor cells, as a recombinant Newcastle disease virus containing a human PTEN protein gene.

The invention relates to monascus orotic acid-5'-phosphoric acid decarboxylase genes and application thereof, belonging to the technical field of microbe gene. The invention comprises the monascus orotic acid-5'-phosphoric acid decarboxylase genes with an SEQ ID NO.1 sequence or homologous compounds which have at least 80 percent homology with the SEQ ID NO.1 sequence and amino acid sequences coded by the genes or the homologous compounds; in a gene construction, the genes or the homologous compounds are effectively connected with one or more regulating signals; and the invention also comprises the application of the genes or the homologous compounds in monascuses as a selective marker. The invention constructs uracil auxotrophs monascuses with stable inheritance by the way of genetic engineering, and the bacterial strains not only are convenient for the genetic transformation and the screening of recombination bacterial strain but also maintain the physiological-biochemical characteristics of wild type bacterial strains, are favorable for the culture of the recombination bacterial strains and the effective expression of foreign proteins, and have relatively high industrial application value.